122 related articles for article (PubMed ID: 20049531)
21. European audit of current practice in diagnosis and treatment of childhood growth hormone deficiency.
Juul A; Bernasconi S; Clayton PE; Kiess W; DeMuinck-Keizer Schrama S;
Horm Res; 2002; 58(5):233-41. PubMed ID: 12401943
[TBL] [Abstract][Full Text] [Related]
22. Late-onset Myoclonic Seizure in a 78-year-old Woman with Gaucher Disease.
Yamaguchi-Takegami N; Takahashi A; Mitsui J; Sugiyama Y; Chikada A; Porto KJL; Takegami N; Sakuishi K; Ishiura H; Yamada K; Shimizu J; Tsuji S; Toda T
Intern Med; 2024 Mar; 63(6):861-865. PubMed ID: 37558486
[TBL] [Abstract][Full Text] [Related]
23. A novel genotype c.1228C>G/c.1448C-1498C (L371V/Rec-NciI) in a 3-year-old child with type 1 Gaucher disease.
Yassin NA; Muwakkit SA; Ibrahim AO; Kayim IM; Habbal MZ; Chamseddine NM; Musallam KM; Shamseddine AI
J Appl Genet; 2008; 49(4):421-4. PubMed ID: 19029690
[TBL] [Abstract][Full Text] [Related]
24. Long-term bone mineral density response to enzyme replacement therapy in a retrospective pediatric cohort of Gaucher patients.
Ciana G; Deroma L; Franzil AM; Dardis A; Bembi B
J Inherit Metab Dis; 2012 Nov; 35(6):1101-6. PubMed ID: 22441841
[TBL] [Abstract][Full Text] [Related]
25. Gaucher disease: A 10 year old girl with anemia and huge spelenomegaly (a case report).
Davarian A; Mirbehbahani NB
Pak J Biol Sci; 2008 Apr; 11(7):1063-5. PubMed ID: 18810981
[TBL] [Abstract][Full Text] [Related]
26. [Clinical outcomes of 2 pediatric patients with Gaucher's disease in enzyme replacement therapy for 9 years].
Quijada Fraile P; Martín Hernández E; Teresa García-Silva M
Med Clin (Barc); 2011 Sep; 137 Suppl 1():43-5. PubMed ID: 22230125
[TBL] [Abstract][Full Text] [Related]
27. Acquired von Willebrand syndrome in patients with Gaucher disease.
Mitrovic M; Elezovic I; Miljic P; Suvajdzic N
Blood Cells Mol Dis; 2014 Apr; 52(4):205-7. PubMed ID: 24275154
[TBL] [Abstract][Full Text] [Related]
28. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
Séllos-Moura M; Barzegar S; Pan L; Shi P; Oommen S; Durant J; Ruiz JA
J Immunol Methods; 2011 Oct; 373(1-2):45-53. PubMed ID: 21846471
[TBL] [Abstract][Full Text] [Related]
29. An unusual combination of Klinefelter syndrome and growth hormone deficiency in a prepubertal child.
Ramesh J; Nagasatyavani M; Venkateswarlu J; Nagender J
J Clin Res Pediatr Endocrinol; 2014 Sep; 6(3):187-9. PubMed ID: 25241616
[TBL] [Abstract][Full Text] [Related]
30. Impact of imiglucerase supply constraint on the therapeutic management and course of disease in French patients with Gaucher disease type 1.
Stirnemann J; Rose C; Serratrice C; Dalbies F; Lidove O; Masseau A; Pers YM; Baron C; Belmatoug N
Orphanet J Rare Dis; 2015 May; 10():62. PubMed ID: 25968608
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease.
Zimran A; Gonzalez-Rodriguez DE; Abrahamov A; Elstein D; Paz A; Brill-Almon E; Chertkoff R
Blood Cells Mol Dis; 2015 Jan; 54(1):9-16. PubMed ID: 25453586
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
Elstein D; Mehta A; Hughes DA; Giraldo P; Charrow J; Smith L; Shankar SP; Hangartner TN; Kunes Y; Wang N; Crombez E; Zimran A
Am J Hematol; 2015 Jul; 90(7):592-7. PubMed ID: 25776130
[TBL] [Abstract][Full Text] [Related]
33. Mass spectrometric quantification of glucosylsphingosine in plasma and urine of type 1 Gaucher patients using an isotope standard.
Mirzaian M; Wisse P; Ferraz MJ; Gold H; Donker-Koopman WE; Verhoek M; Overkleeft HS; Boot RG; Kramer G; Dekker N; Aerts JM
Blood Cells Mol Dis; 2015 Apr; 54(4):307-14. PubMed ID: 25842368
[TBL] [Abstract][Full Text] [Related]
34. [Safety of use of velaglucerase in 2 patients with type 1 Gaucher's disease].
Latre P; Giraldo P
Med Clin (Barc); 2011 Sep; 137 Suppl 1():39-42. PubMed ID: 22230124
[TBL] [Abstract][Full Text] [Related]
35. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
36. The management of Gaucher disease in developing countries: a successful experience in Southern Brazil.
Krug BC; Schwartz IV; Lopes de Oliveira F; Alegra T; Campos Martins NL; Todeschini LA; Picon PD
Public Health Genomics; 2010; 13(1):27-33. PubMed ID: 19407439
[TBL] [Abstract][Full Text] [Related]
37. [Tuberculous sacroiliitis in a patient with Gaucher disease].
Lukina EA; Mamonov VE; Lukina KA; Khomenko VA; Pisetskiĭ MM; Iatsyk GA
Ter Arkh; 2013; 85(7):87-9. PubMed ID: 24137954
[TBL] [Abstract][Full Text] [Related]
38. Effect on adult height of pubertal growth hormone retesting and withdrawal of therapy in patients with previously diagnosed growth hormone deficiency.
Zucchini S; Pirazzoli P; Baronio F; Gennari M; Bal MO; Balsamo A; Gualandi S; Cicognani A
J Clin Endocrinol Metab; 2006 Nov; 91(11):4271-6. PubMed ID: 16912138
[TBL] [Abstract][Full Text] [Related]
39. Coeliac children treated for growth hormone deficiency reach normal final height.
Meazza C; Pagani S; Messini B; Cardinale GM; Mastrangelo C; Citro G; Delvecchio M; Tinelli C; Corazza GR; Bozzola M
Clin Endocrinol (Oxf); 2011 Jun; 74(6):791-2. PubMed ID: 21166689
[No Abstract] [Full Text] [Related]
40. Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
Cappellini MD; Carubbi F; Di Rocco M; Giona F; Giuffrida G
Blood Cells Mol Dis; 2023 Jan; 98():102705. PubMed ID: 36327675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
